Publications by authors named "Janet Addison"

Claim this Profile
C
Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.
Bruno Fautrel, Yoram Bouhnik, Carine Salliot, Franck Carbonnel, Mathurin Fumery, Janet Addison

Drugs Real World Outcomes· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.
Bruno Fautrel, Yoram Bouhnik, Carine Salliot, Franck Carbonnel, Mathurin Fumery, Janet Addison

Drugs Real World Outcomes· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised, crossover trial exploring the patient perspective and effectiveness of biosimilar adalimumab transition: IBD reference and biosimilar adalimumab cross over study (iBaSS).
David Young, Clare Harris, Sohail Rahmany, Inês Iria, João Gonçalves, Janet Addison

Int J Clin Pharm· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48).
Xiaomei Leng, Piotr Leszczyński, Slawomir Jeka, Shengyun Liu, Huaxiang Liu, Janet Addison

Arthritis Res Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial.
Xiaomei Leng, Piotr Leszczyński, Sławomir Jeka, Sheng-Yun Liu, Huaxiang Liu, Janet Addison

Lancet Rheumatol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PERFUSE study: The experience of patients receiving Adalimumab biosimilar SB5.
Yoram Bouhnik, Franck Carbonnel, Mathurin Fumery, Mathurin Flamant, Anne Buisson, Janet Addison

Dig Liver Dis· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease.
Ulf Müller-Ladner, Axel Dignass, Karl Gaffney, Deepak Jadon, Marco Matucci-Cerinic, Janet Addison

BioDrugs· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Premature morbidity and mortality associated with potentially undiagnosed familial hypercholesterolemia in the general population.
Kausik K Ray, Demetris Pillas, Savvas Hadjiphilippou, Kamlesh Khunti, Sreenivasa Rao Kondapally Seshasai, Janet Addison

Am J Prev Cardiol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PERFUSE: Non-Interventional Cohort Study of Patients Receiving Infliximab Biosimilar SB2: Results in Pediatric Patients.
Christine Martinez-Vinson, Anaïs Lemoine, Yoram Bouhnik, Ben Braithwaite, Audrey Fohlen-Weill, Janet Addison

J Pediatr Gastroenterol Nutr· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE study.
Bruno Fautrel, Yoram Bouhnik, Philippe Dieude, Pascal Richette, Maxime Dougados, Janet Addison

Rheumatol Adv Pract· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PERFUSE: a French non-interventional study of patients with inflammatory bowel disease receiving infliximab biosimilar SB2: a 12-month analysis.
Yoram Bouhnik, Bruno Fautrel, Laurent Beaugerie, Anne-Laure Pelletier, Christine Martinez-Vinson, Janet Addison

Therap Adv Gastroenterol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BENEFIT: real-world effectiveness of SB4 after transition from reference etanercept in rheumatoid arthritis and axial spondyloarthritis.
Carlo Selmi, Klaus Krüger, Alain Cantagrel, Miguel Angel Abad Hernández, Ulrich Freudensprung, Janet Addison

Clin Exp Rheumatol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review.
Hans C Ebbers, Burkhard Pieper, Amine Issa, Janet Addison, Ulrich Freudensprung

Rheumatol Ther· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of High and Very High-Risk Subjects with Familial Hypercholesterolemia: Results from an Observational Study in Bulgaria.
Ivo S Petrov, Arman Sh Postadzhiyan, Mariya P Tokmakova, Lyudmila G Kitova, Svetlin N Tsonev, Janet Addison

Folia Med (Plovdiv)· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study.
Jan-Christoph Galle, Janet Addison, Michael G Suranyi, Kathleen Claes, Salvatore Di Giulio

Nephrol Dial Transplant· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammation Modifies the Paradoxical Association between Body Mass Index and Mortality in Hemodialysis Patients.
Peter Stenvinkel, Iain A Gillespie, Jamie Tunks, Janet Addison, Florian Kronenberg

J Am Soc Nephrol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study.
Franz Schaefer, Bernd Hoppe, Therese Jungraithmayr, Günter Klaus, Lars Pape, Janet Addison

Pediatr Nephrol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preservation of anemia control and weekly ESA dosage after conversion from PEG-Epoetin beta to darbepoetin alfa in adult hemodialysis patients: the TRANSFORM study.
Jan Donck, Lourdes Gonzalez-Tabares, Jacques Chanliau, Heike Martin, Kyriaki Stamatelou, Janet Addison

Adv Ther· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM study.
Peter Choi, Mourad Farouk, Nick Manamley, Janet Addison

Adv Ther· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study.
Jan-Christoph Galle, Kathleen Claes, Istvan Kiss, Christopher G Winearls, Hans Herlitz, Janet Addison

Nephrol Dial Transplant· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicity of methyl tert butyl ether to soil invertebrates (springtails: Folsomia candida, Proisotoma minuta, and Onychiurus folsomi) and lettuce (Lactuca sativa).
Matthew Dodd, Janet A Addison

Environ Toxicol Chem· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis